Moleculin Biotech (MBRX) to Release Quarterly Earnings on Monday

Moleculin Biotech (NASDAQ:MBRX) is anticipated to post its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect Moleculin Biotech to post earnings of ($1.69) per share for the quarter. Individuals may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 13, 2026 at 8:30 AM ET.

Moleculin Biotech Trading Down 1.4%

Shares of Moleculin Biotech stock traded down $0.04 during trading hours on Monday, hitting $2.48. 50,592 shares of the company were exchanged, compared to its average volume of 153,414. Moleculin Biotech has a 1 year low of $1.79 and a 1 year high of $28.61. The business has a 50-day moving average of $2.34 and a 200-day moving average of $5.30. The stock has a market capitalization of $13.22 million, a price-to-earnings ratio of -0.08 and a beta of 1.74.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC acquired a new position in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned 1.11% of Moleculin Biotech at the end of the most recent reporting period. 15.52% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. HC Wainwright restated a “buy” rating and set a $22.00 price target on shares of Moleculin Biotech in a research note on Tuesday, March 24th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Moleculin Biotech in a report on Tuesday, April 21st. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Moleculin Biotech has an average rating of “Hold” and an average target price of $22.00.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.